Factors and timing of decreased adherence to S-1 in postoperative docetaxel + S-1 therapy for gastric cancer. Investigation of synergistic effects in trials of combination therapies with ...

2024年12月4日，北京大学肿瘤医院暨北京市肿瘤防治研究所、消化系肿瘤整合防治全国重点实验室、恶性肿瘤转化研究北京市重点实验室季加孚教授、沈琳教授团队在《自然通讯》（Nature Medicine）杂志上发表了题为“First-line ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a market capitalization of approximately $95 million, reported positive outcomes from its ...

Tislelizumab-jsgr approved with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing significant survival benefits. RATIONALE-305 study demonstrated a 20% ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

H.C. Wainwright analysts have reduced the price target for ALX Oncology (NASDAQ:ALXO) shares to $5 from the previous $25 ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on ALX Oncology Holdings (ALXO – Research Report). The ...

The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day.